PEDIATRIC ONCOLOGY GROUP - UNIVERSITY OF FLORIDA

在POG的过去五年里， 研究和全新的癌症治疗方法。 这种努力要求 集团和机构内部的权责发生制分工， 科学投入和机构特征。 积极的前期治疗 是治疗大多数恶性肿瘤的最有效的方法 单一药剂 抗药性疾病的治疗最终是徒劳的， 适应治疗结构的信息正变得越来越多， 更重要的是制定有效的治疗方案。 在美国， f我们已经（1）增加了基础科学的努力，以解决原则 （2）开发了FDA批准的骨髓净化技术 利用单克隆抗体和磁性微球治疗高 神经母细胞瘤的风险，这导致DFS增加了五倍。 这些 试点研究现已成为全集团范围的项目。 这些技术在应用时 对cALLa的治疗发现是想要的， 显然是强制性的。 组合MoAb-微球与 化疗清除是所有这些患者的合理选择， 同种异体移植是不可行的。 我们成功的无血缘关系的捐赠骨髓 移植程序可供全组使用。 我们已经完成了 基础科学的方法，旨在区分移植与 宿主疾病和移植物与白血病使用抗CD 8单克隆抗体。 这类研究 成功地进行了成人使用抗CD 8和C。 我们有 显示高风险尤文氏肉瘤可以有效地治疗， 大剂量治疗和骨髓拯救，它也准备在全集团范围内 使用. 骨肉瘤四药轮换治疗的临床资料 并不比其他任何最好的治疗方法更好。 下一个OS研究将 包括在手术前用骨髓拯救进行大剂量治疗。 我们有 响应POG的要求，开始骨髓移植， 脑瘤和淋巴瘤。 我们将继续发展（1）长期 骨髓自我更新培养系统，（2）生长因子研究和（3） 聚合酶链反应研究（用于MRD检测），同时积极 参与所有POG计划，这一点可以通过我们增加的 在这五年里，我们被杰克逊维尔 （大学医院/内穆尔诊所）机构纳入我们的计划，增加了一个 卫星（迈阿密儿童医院）和附属机构， 在查尔斯顿的南卡罗来纳州，努力确保没有孩子 得不到最好的药物 机构职能体系

The past five years in POG saw stablization and refinement in pre-existing studies and entirely new approaches to cancer care. Such endeavors mandate divisions of labor within groups and institutions in terms of accrual, scientific input, and institutional features. Aggressive up-front therapy is the most effective regimen for most malignant processes. Single agent therapy for resistant disease is eventually fruitless, and genetic information adapted into the fabric of therapy is becoming increasingly more vital to the development of effective treatment programs. At the U of F we have (1) increased basic science endeavors so as to address principles of therapy, and (2) developed FDA approved marrow purging techniques utilizing monoclonalantibodies and magnetic microspheres for treating high risk neuroblastoma, which resulted in a five fold increase in DFS. These pilot studies are now group-wide projects. These techniques when applied to treatment of cALLa were found to be wanting and a reapprisal was obviously mandated. Combination MoAb-microspheres in concert with chemotherapy purging is the reasonable choice for all such patients in whom allografting is not feasible. Our successful, unrelated donor marrow transplant program is available for group-wide use. We have competed the basic science for an approach designed to distinguish between Graft vs. Host Disease and Graft vs. Leukemia using MoAb to CD 8. Such studies have been successfully carried out in adults using anti-CD 8 and C. We have shown that high risk Ewing's sarcoma can be effectively treated with megadose therapy and marrow rescue and it, too, is ready for group-wide use. Our data on osteosarcoma therapy with four drug rotational therapy are no better than any other best therapy. The next o.s. study will include megadose therapy with marrow rescue prior to surgery. We have responded to POG's request to initiate bone marrow transplantation for brain tumors and lymphomas. We will continue to develop (1) long term marrow self-renewing culture systems, (2) growth factor studies and (3) polymerase chain reaction studies (for MRD detection) whilst actively participating in all POG programs as attested by our increased accural over the five year span during which time we absorbed by the Jacksonville (University Hospital/Nemours Clinic) institutions into our program, added a satellite (Miami Children's Hospital), and an affiliate, University of South Carolina at Charleston, efforts designed to be certain that no child with cancer is denied best available medicine at best available institutions.